Dissemin is shutting down on January 1st, 2025

Published in

Future Medicine, Nanomedicine, 23(16), p. 2095-2115, 2021

DOI: 10.2217/nnm-2021-0164

Links

Tools

Export citation

Search in Google Scholar

Development of bozepinib-loaded nanocapsules for nose-to-brain delivery: preclinical evaluation in glioblastoma

Journal article published in 2021 by Amanda de Fraga Dias ORCID, Danieli Rosane Dallemole ORCID, Franciele Aline Bruinsmann ORCID, Luiz Fernando Lopes Silva ORCID, Olga Cruz-López ORCID, Ana Conejo-García ORCID, Ana Maria Oliveira Battastini ORCID, Joaquín María Campos ORCID, Silvia Stanisçuaski Guterres ORCID, Adriana Raffin Pohlmann ORCID, Fabrício Figueiró ORCID
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Aim: To develop and characterize bozepinib-loaded lipid-core nanocapsules (BZP-LNC+) as a potential treatment for glioblastoma (GBM). Methods: Characterization of nanocapsules was performed by diameter, polydispersity index, Zeta potential, pH and encapsulation efficiency. GBM cell viability, cell cycle and Annexin/PI were evaluated after BZP-LNC+ treatment. Synergism between BZP-LNC+ and temozolomide (TMZ) was performed by CompuSyn software and confirmed in vitro and in vivo. Results: BZP-LNC+ showed adequate particle sizes, positive Zeta potential, narrow size distribution and high encapsulation efficiency. BZP-LNC+ reduces GBM growth by inducing apoptosis. BZP-LNC+ and TMZ showed synergistic effect in vitro and reduced the in vivo glioma growth by approximately 81%. Conclusion: The present study provides proof-of-principle insights for the combination of these drugs for GBM treatment.